Year All20252024202320222021202020192018201720162015201420122011 Apr 25, 2022 Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) Apr 12, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Apr 11, 2022 Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor Apr 7, 2022 Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings Apr 4, 2022 Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults Mar 9, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Mar 2, 2022 Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference Feb 28, 2022 Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Feb 24, 2022 Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners Feb 22, 2022 Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022